Catalyst Event
LigaChem Biosciences Inc (141080) · Earnings Release
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
3/23/2026, 12:00:00 AM
Full-year 2025 earnings released. The company reported a significant increase in R&D expenses to 217.1 billion KRW, leading to an operating loss of 106.5 billion KRW despite revenue growth from technology transfers. A medium price impact is estimated due to the scale of the operating loss expected.
Korean Translation
2025년 연간 실적 발표. 기술이전수익 증가에도 불구하고 연구개발비가 2171억원을 기록하며 1065억원의 영업손실을 기록함. 대규모 영업손실 발생으로 인해 주가에 중간 수준의 영향이 예상됨.
Related Recent Events
Samsung Biologics Co Ltd (207940) · Earnings Release
Q1 2026 earnings release scheduled.
4/29/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Decided to cancel 9.11 million treasury shares (approx. 4% of total outstanding shares) worth about KRW 1.7154 trillion for shareholder value enhancement, as resolved at the annual general meeting on March 24, 2026. High impact is estimated due to the significant scale of the cancellation. The cancellation on April 1, 2026 is scheduled.
4/1/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The 41st Annual General Meeting of Shareholders is scheduled for March 31, 2026. Agenda items include the approval of the 2025 financial statements and the appointment of new directors. scheduled
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
20th Annual General Meeting of Shareholders scheduled. Agenda includes approval of 2025 financial statements, appointment of a new internal director, and approval of director compensation limits. A low price impact is estimated as the agenda consists of routine administrative items scheduled.
3/31/2026, 12:00:00 AM
Alteogen Inc (196170) · Other
Alteogen announced an exclusive license agreement with Biogen for its ALT-B4 technology worth up to $579 million on 2026-03-25. A high price impact (>10%) is estimated due to the substantial contract value and strategic partnership.
3/25/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Entered into a license-in agreement with GoBioLab for three microbiome-based drug candidates for intestinal diseases. The deal is worth up to KRW 205.2 billion, including an upfront payment of KRW 1 billion.
3/25/2026, 12:00:00 AM